Latest Content

Long-term CATNON trial results show radiotherapy followed by adjuvant temozolomide extends survival in patients with newly diagnosed anaplastic glioma.

Stick your toes in the ocean. Feed the koi. Play make-believe carwash with a toddler. Hold his hand because he asks you to. Be present.

Dr. Anne Peled co-developed the sensation-preserving mastectomy she received after her second diagnosis of breast cancer.

Experts highlight key themes from the ASCO GI Cancers Symposium, including the growing role of AI and an increased emphasis on patient-centered decision-making.

Outpatient CD19 CAR-NK plus rituximab led to complete remissions up to 15 months in patients with Waldenström Non-Hodgkin lymphoma.

The allogeneic CAR-T therapy aims to expand urgently needed options for children and adults with aggressive T-cell blood cancers.

The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare blood cancer.

CURE spoke with advocate Karen Hoyt about liver cancer, liver disease, and liver health, highlighting silent risk, misconceptions and need for awareness.

Dr. Benjamin Jon Golas outlines pancreatic cancer care, including surgery, chemotherapy, radiation and emerging targeted therapies at specialized centers.

A patient with bladder cancer and CLL reflects on how the Japanese art of Ikebana taught acceptance, presence and self-compassion while living with cancer.

A vaccine combined with Keytruda is associated with a 49% reduction in the risk of recurrence or death.

The FDA accepted a new drug application for gedatolisib for patients with HR+, HER2-, PIK3CA wild-type advanced breast cancer.

In patients with high-risk melanoma, intismeran autogene and Keytruda reduced the risk of recurrence or death compared to Keytruda alone.